The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00 ...

Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

In a report released today, Tiago Fauth from Wells Fargo downgraded United Therapeutics (UTHR – Research Report) to a Hold, with a price target ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Wells Fargo downgraded United Therapeutics (UTHR) to Equal Weight from Overweight with a price target of $314, down from $395.Stay Ahead of the ...

Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. UTHR is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...